I don't see the GLP-1 drugs as an imminent threat to ResMed's business. But their impact will ... It makes sense that people would keep using the CPAP machines because they are still obese and ...

Shares of ResMed, a maker of CPAP and other sleep-apnea airway machines, have dropped because of new GLP-1 developments. It’s an overreaction ... “We don’t see GLP-1s shrinking the market.” ...

ResMed CEO on Philips' return to CPAP market: 'Game on' And that predicted ... funnel because they tried a pill and it didn’t work, that’s good for us, too.” ...

Healthcare technology company ResMed's (NYSE: RMD) stock wasn't quite the picture of health ... of its continuous positive airway pressure (CPAP) products that help treat sleep apnea.

When Philips first began its massive recall of more than 5 million CPAP and ... Farrell didn’t disclose specific numbers about those volume increases, Rob Douglas, ResMed’s president and ...

ResMed dominates an enormous, underdiagnosed market with recurring revenue and digital health leadership. Read why RMD stock ...

CPAP providers say they can’t fault Resmed for expanding its reach into the sleep market, but there’s always concern that a “Goliath” will eventually muscle smaller companies out of the way.

He’s also the ... the CEO of ResMed, looked refreshed, despite a post-presentation cocktail reception. If the sleep tech magnate could have used more shuteye, he didn’t show it.

ResMed commenced paying a dividend in fiscal 2013 and doesn't have a ... in the CPAP category. This may reflect higher reimbursement support. In addition, we think ResMed’s patent portfolio ...